euro-cancer-2018-scientifictracks

2 / 36

Volume 10 Journal of Cancer Science & Therapy
ISSN: 1948-5956 Euro Cancer 2018
July 23-25, 2018
Page 46
conferenceseries.com
July 23-25, 2018 | Rome, Italy
29th Euro-Global Summit on
Cancer Therapy & Radiation Oncology
Guilin Tang, J Cancer Sci Ther 2018, Volume 10
DOI: 10.4172/1948-5956-C8-144
Clonal cytogenetic abnormalities of undetermined significance
Myelodysplastic syndromes are a group of hematopoietic stem cell diseases characterized by cytopenia(s), morphological
dysplasia, and clonal hematopoiesis. In some patients, the cause of cytopenia(s) is uncertain, even after thorough clinical
and laboratory evaluation. Evidence of clonal hematopoiesis has been used to support a diagnosis of myelodysplastic syndrome
in this setting. In patients with cytopenia(s), the presence of clonal cytogenetic abnormalities, except for +8, del (20q) and –Y,
can serve as presumptive evidence of myelodysplastic syndrome. Recent advances in next generation sequencing have detected
myeloid neoplasm-related mutations in patients who do not meet the diagnostic criteria for myelodysplastic syndrome. Various
terms have been adopted to describe these cases, including clonal hematopoiesis of indeterminate potential and clonal cytopenia
of undetermined significance. Similarly, studies have shown that certain chromosomal abnormalities, including ones commonly
detected inmyelodysplastic syndrome, may not be associated necessarily with an underlyingmyelodysplastic syndrome.These clonal
cytogenetic abnormalities of undetermined significance (CCAUS) are similar to clonal hematopoiesis of indeterminate potential
and clonal cytopenia of undetermined significance. Here, we review the features of CCAUS, distinguishing CCAUS from clonal
cytogenetic abnormalities associated with myelodysplastic syndrome, and the potential impact of CCAUS on patient management..
Recent Publications
1. ZuoW, Wang S A, DiNardo C, YabeM, Li S, et al. (2017) Acute leukemia andmyelodysplastic syndromes with chromosomal
rearrangement involving 11q23 locus, but not MLL gene. J Clin Pathol 70:244–249.
2. Goswami R S, Wang S A, DiNardo C, Tang Z, Li Y, et al. (2016). Newly emerged isolated del(7q) in patients with prior
cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms. Mod Pathol 29:727–34.
3. Tang Z, Li Y, Wang S A, Hu S, Li S, et al. (2016). Clinical significance of acquired loss of the X chromosome in bone marrow.
Leuk Res 47:109–13.
Biography
Guilin Tang is a Hematopathologist and Cytogeneticist, Section Chief of Clinical Cytogenetic Laboratory in the Department of Hematopathology, and Adjunct Medical
Director of the Department of School of Health Professions. Her clinical interests include diagnosis of hematologic neoplasms (both leukemia and lymphomas) and cancer
cytogenetics. Her major research interest is the characterization and risk stratification of cytogenetic abnormalities in various types of hematological malignancies, to
better understand the pathogenesis, identify new clinicopathologic entities and predict patient prognosis. She is also very interested in characterization of clinically indolent
cytogenetic clones (clonal cytogenetic abnormalities of undetermined significance), especially those emerged following cytotoxic therapies.
Guilin Tang
University of Texas, MD Anderson Cancer Center, USA